GH Research (NASDAQ:GHRS) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of GH Research (NASDAQ:GHRS) in a research report report published on Wednesday, Benzinga reports. HC Wainwright currently has a $40.00 price objective on the stock. HC Wainwright also issued estimates for GH Research’s Q1 2025 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.22) EPS and Q4 2025 earnings at ($0.20) EPS.

Separately, Canaccord Genuity Group increased their price target on GH Research from $30.00 to $31.00 and gave the company a buy rating in a research note on Monday, May 6th.

GH Research Price Performance

Shares of GHRS stock opened at $11.92 on Wednesday. The company has a fifty day moving average price of $12.20 and a two-hundred day moving average price of $10.66. GH Research has a one year low of $5.05 and a one year high of $14.99. The stock has a market cap of $620.20 million, a P/E ratio of -19.23 and a beta of 0.86.

GH Research (NASDAQ:GHRS) last issued its earnings results on Friday, May 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.07. As a group, equities research analysts anticipate that GH Research will post -0.84 EPS for the current fiscal year.

Institutional Investors Weigh In On GH Research

A number of institutional investors have recently made changes to their positions in the company. AdvisorShares Investments LLC boosted its stake in GH Research by 4.3% in the 4th quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock valued at $280,000 after purchasing an additional 1,977 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in GH Research by 14.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 106,363 shares of the company’s stock valued at $617,000 after purchasing an additional 13,579 shares during the period. Lynx1 Capital Management LP grew its position in shares of GH Research by 80.1% during the 1st quarter. Lynx1 Capital Management LP now owns 3,310,563 shares of the company’s stock worth $35,291,000 after purchasing an additional 1,471,946 shares in the last quarter. RA Capital Management L.P. increased its holdings in shares of GH Research by 11.9% during the first quarter. RA Capital Management L.P. now owns 6,251,714 shares of the company’s stock worth $66,643,000 after purchasing an additional 664,381 shares during the period. Finally, BVF Inc. IL increased its stake in GH Research by 12.1% during the 4th quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock worth $60,321,000 after acquiring an additional 1,125,000 shares during the period. Institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).